163 related articles for article (PubMed ID: 8265981)
41. Interleukin-2 bolus therapy induces immediate and selective disappearance from peripheral blood of all lymphocyte subpopulations displaying natural killer activity: role of cell adhesion to endothelium.
Salvo G; Samoggia P; Masciulli R; Boccoli G; Allavena P; Mariani G; Bullo A; Montesoro E; Bulgarini D; Carlini P
Eur J Cancer; 1992; 28A(4-5):818-25. PubMed ID: 1524901
[TBL] [Abstract][Full Text] [Related]
42. Treatment of recurrent malignant glioma by repeated intracerebral injections of human recombinant interleukin-2 alone or in combination with systemic interferon-alpha. Results of a phase I clinical trial.
Merchant RE; McVicar DW; Merchant LH; Young HF
J Neurooncol; 1992 Jan; 12(1):75-83. PubMed ID: 1541981
[TBL] [Abstract][Full Text] [Related]
43. Role of monocytes in the expansion of human activated natural killer cells.
Miller JS; Oelkers S; Verfaillie C; McGlave P
Blood; 1992 Nov; 80(9):2221-9. PubMed ID: 1421393
[TBL] [Abstract][Full Text] [Related]
44. Lack of correlation between peripheral blood lymphokine-activated killer (LAK) cell function and clinical response in patients with advanced malignant melanoma receiving recombinant interleukin 2.
Ghosh AK; Dazzi H; Thatcher N; Moore M
Int J Cancer; 1989 Mar; 43(3):410-4. PubMed ID: 2784419
[TBL] [Abstract][Full Text] [Related]
45. Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation.
Soiffer RJ; Murray C; Cochran K; Cameron C; Wang E; Schow PW; Daley JF; Ritz J
Blood; 1992 Jan; 79(2):517-26. PubMed ID: 1730094
[TBL] [Abstract][Full Text] [Related]
46. Thyroid function abnormalities associated with the chronic outpatient administration of recombinant interleukin-2 and recombinant interferon-alpha.
Jacobs EL; Clare-Salzler MJ; Chopra IJ; Figlin RA
J Immunother (1991); 1991 Dec; 10(6):448-55. PubMed ID: 1768679
[TBL] [Abstract][Full Text] [Related]
47. Immunological evaluation of pediatric cancer patients receiving recombinant interleukin-2 in a phase I trial.
Truitt RL; Piaskowski V; Kirchner P; McOlash L; Camitta BM; Casper JT
J Immunother (1991); 1992 May; 11(4):274-85. PubMed ID: 1599913
[TBL] [Abstract][Full Text] [Related]
48. Chemo-immunotherapy in patients with metastatic melanoma using sequential treatment with dacarbazine and recombinant human interleukin-2: evaluation of hematologic and immunologic parameters and correlation with clinical response.
Isacson R; Kedar E; Barak V; Gazit Z; Yurim O; Kalichman I; Ben-Bassat H; Biran S; Schlesinger M; Franks CR
Immunol Lett; 1992 Jul; 33(2):127-34. PubMed ID: 1446917
[TBL] [Abstract][Full Text] [Related]
49. Recombinant interleukin-2 treatment in patients with metastatic colorectal cancer: effect on natural cytotoxicity.
Park KG; Heys SD; Murray JB; Hayes PD; Ashby JA; Franks CR; Eremin O
Cancer Immunol Immunother; 1992; 35(1):53-8. PubMed ID: 1611623
[TBL] [Abstract][Full Text] [Related]
50. Activation of extracellular signaling regulated kinase in natural killer cells and monocytes following IL-2 stimulation in vitro and in patients undergoing IL-2 immunotherapy: analysis via dual parameter flow-cytometric assay.
Kondadasula SV; Varker KA; Lesinski GB; Benson DM; Lehman A; Olencki T; Monk JP; Kendra K; Carson WE
Cancer Immunol Immunother; 2008 Aug; 57(8):1137-49. PubMed ID: 18193422
[TBL] [Abstract][Full Text] [Related]
51. A Southwest Oncology Group Phase I study of the sequential combination of recombinant interferon-gamma and recombinant interleukin-2 in patients with cancer.
Taylor CW; Chase EM; Whitehead RP; Rinehart JJ; Neidhart JA; Gonzalez R; Bunn PA; Hersh EM
J Immunother (1991); 1992 Apr; 11(3):176-83. PubMed ID: 1515422
[TBL] [Abstract][Full Text] [Related]
52. Treatment of metastatic renal cell cancer patients with recombinant subcutaneous human interleukin-2 and interferon-alpha.
Atzpodien J; Körfer A; Palmer PA; Franks CR; Poliwoda H; Kirchner H
Ann Oncol; 1990 Sep; 1(5):377-8. PubMed ID: 2261378
[TBL] [Abstract][Full Text] [Related]
53. Second line therapy with low-dose subcutaneous interleukin-2 alone in advanced renal cancer patients resistant to interferon-alpha.
Lissoni P; Barni S; Ardizzoia A; Crispino S; Paolorossi F; Archili C; Vaghi M; Tancini G
Eur J Cancer; 1992; 28(1):92-6. PubMed ID: 1567700
[TBL] [Abstract][Full Text] [Related]
54. Leukocyte orchestration in blood and tumour tissue following interleukin-2 based immunotherapy in metastatic renal cell carcinoma.
Donskov F; Bennedsgaard KM; Hokland M; Marcussen N; Fisker R; Madsen HH; Fode K; von der Maase H
Cancer Immunol Immunother; 2004 Aug; 53(8):729-39. PubMed ID: 15088127
[TBL] [Abstract][Full Text] [Related]
55. [Clinical efficacy of recombinant interleukin-2 for renal cell carcinoma and the effect of blood transfusion upon the immune response of these patients].
Fujioka T; Kudo T; Ishikura K; Shiraishi M; Tanji S; Okamoto T; Suzuki K; Koike H; Kumagai K; Ohhori T
Nihon Hinyokika Gakkai Zasshi; 1990 Feb; 81(2):296-303. PubMed ID: 2325327
[TBL] [Abstract][Full Text] [Related]
56. Low-dose interleukin-2 impairs host anti-tumor immunity and inhibits therapeutic responses in a mouse model of melanoma.
Zloza A; Dharmadhikari ND; Huelsmann EJ; Broucek JR; Hughes T; Kohlhapp FJ; Kaufman HL
Cancer Immunol Immunother; 2017 Jan; 66(1):9-16. PubMed ID: 27757560
[TBL] [Abstract][Full Text] [Related]
57. Immunologic study of human recombinant interleukin-2 (low-dose) in patients with advanced renal cell carcinoma.
Marumo K; Muraki J; Ueno M; Tachibana M; Deguchi N; Baba S; Jitsukawa S; Hata M; Tazaki H
Urology; 1989 Mar; 33(3):219-25. PubMed ID: 2784018
[TBL] [Abstract][Full Text] [Related]
58. [Effect of Low-Dose Recombinant Interleukin-2 Therapy on Immunocyte Subsets in Children with Solid Tumor].
Lei JY; Li Y; Li CM; Xiong XL; Feng CC; Weng WJ; Peng XM; Zhou DH; Huang K
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):445-449. PubMed ID: 38660850
[TBL] [Abstract][Full Text] [Related]
59. A phase I study of an outpatient regimen of recombinant human interleukin-2 and alpha-2a-interferon in patients with solid tumors.
Huberman M; Bering H; Fallon B; Tessitore J; Sonnenborn H; Paul S; Zeffren J; Levitt D; Groopman J
Cancer; 1991 Oct; 68(8):1708-13. PubMed ID: 1913512
[TBL] [Abstract][Full Text] [Related]
60. A phase I study of interleukin-2 in children with cancer and evaluation of clinical and immunologic status during therapy. A Pediatric Oncology Group Study.
Nasr S; McKolanis J; Pais R; Findley H; Hnath R; Waldrep K; Ragab AH
Cancer; 1989 Aug; 64(4):783-8. PubMed ID: 2787201
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
